Tribune News Service
New Delhi, July 8
Good news for diabetes patients as Ahmedabad-based Zydus Lifesciences on Friday launched top anti-diabetic drug molecule Sitagliptin in India under the brand names Sitaglyn and Siglyn to address Type-2 diabetes.
Sitaglyn and Siglyn will add on to a comprehensive solution for the management of Type-2 diabetes by providing access to quality care to patients at an affordable cost, approximately 60 per cent less than the originator.
The launch of the generic version has become possible after US pharma major Merck drug’s Sitagliptin, previously marketed under the brand Januvia, fell off patent.
More Indian pharma companies are expected to announce generic versions now. While the original drug regime cost around Rs 450 a day treatment, the new will cost less than Rs 18 a day, industry sources said.
“Sitaglyn and Siglyn offer an oral solution to the patients providing ease of convenience and better compliance. Sitagliptin is the gold standard drug with over 62 per cent market share in the global market. The drug has a proven safety profile,” Zydus said.
With more than 77 million active patients, India is the diabetes capital of the world after China.
For all the latest Health News Click Here
For the latest news and updates, follow us on Google News.
Denial of responsibility! NewsBit.us is an automatic aggregator around the global media. All the content are available free on Internet. We have just arranged it in one platform for educational purpose only. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, all materials to their authors. If you are the owner of the content and do not want us to publish your materials on our website, please contact us by email – [email protected]. The content will be deleted within 24 hours.
